Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:10:44 2024-03-28 pm EDT 5-day change 1st Jan Change
68.78 USD +0.42% Intraday chart for Vaxcyte, Inc. +1.68% +9.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating MT
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants CI
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating MT
Vaxcyte Q4 Loss Widens MT
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing MT
Vaxcyte Prices $750 Million Public Offering at $64 Per Share MT
Vaxcyte Launches Securities Offering; Shares Fall After Hours MT
Sector Update: Health Care Stocks Advance Monday Afternoon MT
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate MT
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate MT
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older CI
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $485,879, According to a Recent SEC Filing MT
Vaxcyte Names Chief People Officer MT
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer CI
Vaxcyte Shares Drop After Clinical Pipeline Updates MT
Vaxcyte Insider Sold Shares Worth $828,915, According to a Recent SEC Filing MT
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise CI
Chart Vaxcyte, Inc.
More charts
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
68.5 USD
Average target price
103.3 USD
Spread / Average Target
+50.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Vaxcyte, Inc. - Nasdaq
  4. News Vaxcyte, Inc.
  5. Vaxcyte Prices Offering of Common Shares, Warrants; Expects $100 Million Gross Proceeds